Fetching the paper…
Reading the bibliography…
Consider the relationship between a regulator (the principal) and an experimenter (the agent) such as a pharmaceutical company.
On the problem of the most efficient tests of statistical hypotheses
Neyman, J. and E. S. Pearson (1933) · 1933
Earlier work this paper cites.
The theory of contracts
Hart, O. and B. Holmström (1987) · 1987
Earlier work this paper cites.
Food and Drug Modernization Act
Pub. L. (1997) · 1997
Earlier work this paper cites.
The Theory of Incentives: The Principal-Agent Model
Laffont, J.-J. and D. Martimort (2001) · 2001
Earlier work this paper cites.
Contract Theory
Bolton, P. and M. Dewatripont (2004) · 2004
Earlier work this paper cites.
The Economics of Contracts: A Primer, 2nd Edition
Salanie, B. (2005) · 2005
Earlier work this paper cites.
Combinatorial agency
Babaioff, M., M. Feldman, and N. Nisan (2006) · 2006
Earlier work this paper cites.
Designing Economic Mechanisms
Hurwicz, L. and S. Reiter (2006) · 2006
Earlier work this paper cites.
Essays on contract theory and organizational economics
Ke, R. (2009) · 2009
Earlier work this paper cites.
Bayesian persuasion
Kamenica, E. and M. Gentzkow (2011) · 2011
Earlier work this paper cites.
Selective trials: A principal-agent approach to randomized controlled experiments
Chassang, S., P. I. Miquel, E. Snowberg, et al. (2012) · 2012
Earlier work this paper cites.
On the use of holdout samples for model selection
Schorfheide, F. and K. I. Wolpin (2012) · 2012
Earlier work this paper cites.
Incentivizing exploration
Frazier, P., D. Kempe, J. Kleinberg, and R. Kleinberg (2014) · 2014
Earlier work this paper cites.
Robustness and linear contracts
Carroll, G. (2015) · 2015
Earlier work this paper cites.
Innovation in the pharmaceutical industry: new estimates of R&D costs
DiMasi, J. A., H. G. Grabowski, and R. W. Hansen (2016) · 2016
Earlier work this paper cites.
Adaptive contract design for crowdsourcing markets: Bandit algorithms for repeated principal-agent problems
Ho, C.-J., A. Slivkins, and J. W. Vaughan (2016) · 2016
Cited alongside, same era.
Estimated costs of pivotal trials for novel therapeutic agents approved by the us food and drug administration, 2015-2016
Moore, T. J., H. Zhang, G. Anderson, and G. C. Alexander (2018) · 2016
Cited alongside, same era.
Characteristics of single pivotal trials supporting regulatory approvals of novel non-orphan, non-oncology drugs in the European Union and United States from 2012- 2016
Morant, A. V., V. Jagalski, and H. T. Vestergaard (2019) · 2016
Cited alongside, same era.
To hold out or not to hold out
Schorfheide, F. and K. I. Wolpin (2016) · 2016
Cited alongside, same era.
An economic theory of statistical testing
Tetenov, A. (2016) · 2016
Cited alongside, same era.
Is the FDA too conservative or too aggressive?: A Bayesian decision analysis of clinical trial design
Isakov, L., A. W. Lo, and V. Montazerhodjat (2019) · 2019
Later among the works it cites.
The growing gap between what the public had been told R&D costs are, and the actual costs
Love, J. (2019) · 2019
Later among the works it cites.
Final summary minutes of the peripheral and central nervous system drugs advisory committee meeting
FDA Center for Drug Evaluation and Research (2020) · 2020
Later among the works it cites.
Safe testing
Grünwald, P., R. de Heide, and W. M. Koolen (2020) · 2020
Later among the works it cites.
Contracts with private cost per unit-of-effort
Alon, T., P. Dütting, and I. Talgam-Cohen (2021) · 2021
Later among the works it cites.
The complexity of contracts
Dütting, P., T. Roughgarden, and I. Talgam-Cohen (2021) · 2021
alphaXiv searches the wider corpus for related work and actual follow-ups.
alphaXiv is searching for related work…
Persuasion bias in science: Can economics help?
Di Tillio, A., M. Ottaviani, and P. N. Sørensen (2017, 10) · 2017
Cited alongside, same era.
Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study
Moore, T. J., J. Heyward, G. Anderson, and G. C. Alexander (2020) · 2017
Cited alongside, same era.
US Food and Drug Administration reasoning in approval decisions when efficacy evidence is borderline, 2013–2018
Janiaud, P., T. Irony, E. Russek-Cohen, and S. N. Goodman (2021) · 2018
Cited alongside, same era.
Optimal estimation when researcher and social preferences are misaligned
Spiess, J. (2018) · 2018
Cited alongside, same era.
Estimated research and development investment needed to bring a new medicine to market, 2009-2018
Wouters, O. J., M. McKee, and J. Luyten (2020) · 2018
Cited alongside, same era.
Simple versus optimal contracts
Dütting, P., T. Roughgarden, and I. Talgam-Cohen (2019) · 2019
Cited alongside, same era.
Biopharma’s biggest sellers – the oldies that just keep giving
Elmhirst, E. and L. Urquhart (2019) · 2019
Cited alongside, same era.
Later among the works it cites.
Contracts under moral hazard and adverse selection
Guruganesh, G., J. Schneider, and J. R. Wang (2021) · 2021
Later among the works it cites.
How much does it cost to research and develop a new drug? A systematic review and assessment
Schlander, M., K. Hernandez-Villafuerte, C.-Y. Cheng, J. Mestre-Ferrandiz, and M. Baumann (2021) · 2021
Later among the works it cites.
Testing by betting: a strategy for statistical and scientific communication
Shafer, G. (2021) · 2021
Later among the works it cites.
(When) should you adjust inferences for multiple hypothesis testing?
Viviano, D., K. Wuthrich, and P. Niehaus (2021) · 2021
Later among the works it cites.
E-values: calibration, combination and applications
Vovk, V. and R. Wang (2021) · 2021
Later among the works it cites.
Bayesian agency: Linear versus tractable contracts
Castiglioni, M., A. Marchesi, and N. Gatti (2022) · 2022
Closest in time.
Screening for experiments
Min, D. (2023) · 2023
Closest in time.
Game-theoretic statistics and safe anytime-valid inference
Ramdas, A., P. Grünwald, V. Vovk, and G. Shafer (2023) · 2023
Closest in time.